Table 4.
Study | n | Technique | Imaging biomarker | Histotype | Treatment |
Lewin et al[107] | 12 | IVIM | f increase | HCC | sorafenib |
Vouche et al[108] | 15 | DWI | ADC increase | HCC | 90Y TARE ± sorafenib |
Hsu et al[109] | 31 | DCE-MRI | Ktrans decrease | HCC | sorafenib+metronomic tegafur/uracil |
Yopp et al[111] | 17 | DCE-MRI | AUC90/AUC180/Ktrans decrease | HCC | bevacizumab |
Jiang et al[112] | 23 | pCT | BF/BV/PS decrease | HCC | bevacizumab + cytotoxic agents |
MTT increase | |||||
Kim et al[113] | 10 | DCE-MRI/DWI | Ktrans/Kep decrease | HCC | sunitinib |
ADC increase | |||||
Sahani et al[114] | 23 | DCE-MRI/DWI | Ktrans/Kep decrease | HCC | sunitinib |
ADC increase | |||||
Kim et al[123] | 35 | pCT | BF decrease | CRC metastases | XELOX, FOLFOX, FOLFIRI |
Schlemmer et al[124] | 24 | pCT | Perfusion decrease | PanNET metastases | Tyrosine-kinase inhibitors |
Anzidei et al[125] | 18 | pCT, DWI | CP decrease | CRC metastases | Oxaliplatinum, capecitabine, bevacizumab |
ADC increase | |||||
De Bruyne et al[127] | 19 | DCE-MRI | AUC decrease | CRC metastases | Bevacizumab |
Vriens et al[129] | 23 | DCE-MRI | Ktrans decrease | CRC metastases | Cytotoxic therapy |
Coenegrachts et al[130] | 10 | DCE-MRI | Kep increase | CRC metastases | Bevacizumab + FOLFIRI |
Deckers et al[126] | 20 | DWI | ADC decrease | CRC metastases | Chemotherapy |
Niwa et al[133] | 63 | DWI | ADC decrease | PDAC | Gemcitabine |
Cuneo et al[134] | 12 | DWI | ADC increase | PDAC | Chemoradiation |
Yao et al[135] | 39 | pCT | BF decrease | PanNET | Bevacizumab ± everolimus |
Miyazaki et al[132] | 20 | DCE-MRI | Distribution volume increase | PanNET metastases | 90Y-octretotide |
n: Number of patients; IVIM: Intravoxel incoherent-motion diffusion-weighted imaging; f: Perfusion fraction; HCC: Hepatocellular carcinoma;
Y TARE: 90Yttrium trans-arterial radioembolization; DWI: Diffusion-weighted imaging; ADC: Apparent diffusion coefficient; DCE-MRI: Dynamic contrast-enhanced MRI; Ktrans: Volume transfer constant; AUC90, AUC180: Area under the curve at 90 and 180 s; pCT: Perfusion computed tomography; BF: Blood flow; BV: Blood volume; PS: Permeability surface; MTT: Mean transit time; Kep: Rate constant; CP: Capillary permeability.